In a significant shift in legislative oversight, the Congressional Budget Office (CBO) has issued a sobering call for a comprehensive re-evaluation of the No Surprises Act (NSA). While the landmark 2020 legislation has successfully achieved its primary objective—shielding American patients from the trauma of unexpected out-of-network medical bills—the CBO now warns that the law’s structural mechanisms may be fueling the very healthcare inflation it was intended to curtail.
For years, the promise of the No Surprises Act was simple: by removing the patient from the financial crossfire of billing disputes between insurers and healthcare providers, the cost of medical care would stabilize. However, new research suggests that the “Independent Dispute Resolution” (IDR) process, designed as a fair arbiter, has instead morphed into a lucrative revenue stream for certain providers, potentially driving up premiums and federal deficits.
The Genesis of the Act: A Legislative Promise
When the No Surprises Act was passed in 2020, it was hailed as a rare bipartisan victory in a polarized Congress. The policy logic was sound: providers often held leverage over insurers by threatening to remain out-of-network, forcing patients to pay exorbitant, non-negotiable fees for emergency care or services at in-network facilities.
The CBO’s initial 2021 forecast projected that the act would lower insurance reimbursements, thereby decreasing monthly premiums for consumers and reducing overall national healthcare spending. For a time, the data supported this optimism. The act successfully eliminated the "surprise" element for millions of patients, and preliminary studies indicated that the mere existence of the law exerted downward pressure on some service costs.
Yet, as the law matured, the economic reality diverged from the theory. The CBO’s latest assessment, released this past Monday, acknowledges a growing disconnect: "Emerging evidence suggests that the law might not have the effects that the CBO anticipated."
Chronology of a Regulatory Backfire
The timeline of the NSA reveals a rapid descent from a consumer-protection success story to a complex systemic issue:
- December 2020: The No Surprises Act is signed into law as part of a year-end spending package, aimed at curbing predatory billing practices.
- January 2022: The Independent Dispute Resolution (IDR) process officially launches. The government estimates approximately 17,000 cases will be handled through this mechanism annually.
- 2023–2024: Data begins to surface showing a massive, unexpected volume of disputes. The arbitration system becomes clogged as medical groups—particularly those backed by private equity—leverage the process to maximize payouts.
- Early 2025: The scale of the issue becomes impossible to ignore. Federal data reveals that in the first half of 2025 alone, providers filed 1.2 million disputes, dwarfing the original 17,000-case projection by several orders of magnitude.
- Late 2025: The CBO formally calls for a deep-dive investigation into the market effects of the NSA, citing concerns that the law is unintentionally inflating healthcare costs.
Supporting Data: A System Under Siege
The numbers behind the current crisis are stark. The IDR process, which was intended to be a rare "last resort," has become a primary business strategy for some entities.
According to the most recent federal data, providers currently win approximately 88% of all surprise billing disputes. When they win, the payouts are often staggering, frequently reaching three to four times the amount of standard, negotiated in-network rates. This disparity creates a perverse incentive structure: if a provider can consistently secure higher payments through the IDR process than they could by negotiating a fair contract with an insurer, they have little economic motivation to join an insurance network.
The surge in case volume is perhaps the most damning statistic. The jump from an anticipated 17,000 cases to over 1.2 million in just six months suggests a systematic, rather than incidental, use of the arbitration process. Critics point to private equity-backed medical groups as the primary drivers of this trend, arguing that these organizations have optimized the IDR process to maximize profit margins at the expense of the broader healthcare ecosystem.
Official Responses and Industry Friction
The CBO’s call for action has ignited a firestorm of debate between the insurance industry and provider organizations.
Insurance advocacy groups have been quick to validate the CBO’s concerns. Chris Bond, a spokesperson for AHIP (America’s Health Insurance Plans), issued a scathing critique of the current landscape. "Provider-driven abuse of the No Surprises Act is adding billions in wasteful spending and raising healthcare costs for everyone," Bond stated. "Policy action is needed to address flawed incentives in the IDR process and protect consumers from unconscionable price gouging by some PE-backed providers and IDR middlemen."
Conversely, many provider groups maintain that the data is being misinterpreted. They argue that the high win rate in arbitration is not evidence of systemic abuse, but rather a reflection of the fact that insurers have historically set in-network reimbursement rates far too low. From this perspective, the IDR process is simply bringing reimbursement levels closer to the actual cost of providing complex medical care.
However, researchers note that even if only a small fraction of claims—less than 0.05%—enter arbitration, the influence on the market is disproportionate. The mere threat of entering the IDR process grants providers immense leverage in contract negotiations, allowing them to demand higher in-network rates by pointing to their potential success in arbitration.
The Macroeconomic Implications: Why It Matters
The implications of this trend extend far beyond the relationship between insurers and hospitals. The CBO has explicitly warned that the current trajectory could have long-term consequences for the federal budget.
"An increase in prices would increase premiums for commercial health insurance and, in turn, lead to larger federal deficits," the agency noted in its recent report. Because a significant portion of commercial health insurance is subsidized through tax exclusions for employer-sponsored coverage, rising premiums directly decrease federal tax revenue.
Furthermore, the "spillover effect" is a significant concern. As commercial rates rise to accommodate higher provider payouts, there is a risk that public programs, such as Medicare and Medicaid, could eventually face pressure to increase their own reimbursement rates to maintain provider access, creating a cycle of inflationary pressure that could ripple across the entire U.S. economy.
Seeking a Path Forward: Is Reform Possible?
Despite the mounting evidence of dysfunction, legislative progress remains stalled. Congress, while generally focused on healthcare affordability, has shown limited appetite for reopening the No Surprises Act—a piece of legislation that was difficult to negotiate the first time around.
Recent efforts by the Department of Health and Human Services (HHS) to implement stricter rules on the IDR process—including mechanisms to filter out ineligible disputes—have been met with mixed reviews. While regulators hope these guardrails will reduce the administrative burden on the system, insurers argue that such measures are merely "band-aids" on a bullet wound.
The Coalition Against Surprise Medical Billing, which represents a broad alliance of insurers and employers, has renewed its call for fundamental structural reform. "A law that was intended to be a deficit reducer is doing the opposite," the group stated. They are pushing for "commonsense guardrails" that would curb the ability of providers to use arbitration as a profit center.
As the CBO continues its investigation, the focus will likely shift toward how to recalibrate the IDR process without undermining the core consumer protections that the public still demands. Whether that will require legislative intervention or further executive-branch rulemaking remains to be seen.
For now, the No Surprises Act stands as a cautionary tale in public policy: the law effectively solved the problem of the patient’s bill, but in doing so, it inadvertently created a new, systemic challenge that may prove to be just as costly, if not more so, in the years to come. The coming months of debate on Capitol Hill will be critical in determining whether the act can be salvaged as a tool for cost containment or if it will remain a source of unchecked healthcare inflation.
